Clinical Trial Results: Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results assess safety and tolerability of a chimeric antigen receptor T-regulatory cell therapy in living donor renal transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Transplant Rejection

Drugs mentioned

• Chimeric antigen receptor T-regulatory cell therapy

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Kidney Transplant Rejection, End Stage Renal Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-07-02